Sino Biopharmaceutical Limited
1177
株式のランク
#1753
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
株価
$0.69080164
時価総額
$12.30B
変化（1日）
2.86%
変化（1年）
-27.78%
国
HK
取引 Sino Biopharmaceutical Limited (1177)
カテゴリー
Healthcare
Sino Biopharmaceutical Limited（1177）の配当利回りの履歴
Sino Biopharmaceutical Limited（銘柄コード: 1177）の配当利回り（TTM）は2023-12-31時点で0.89%です。
過去5年間の平均配当利回り: 1.65%
過去5年間の平均配当利回り: 1.65%
Sino Biopharmaceutical Limited（1177）の2000から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 2026 (TTM) | 2.29% | -35.31% |
| 2024 | 3.54% | 297.75% |
| 2023 | 0.89% | -47.34% |
| 2022 | 1.69% | 50.89% |
| 2021 | 1.12% | 12.00% |
| 2020 | 1.00% | 49.25% |
| 2019 | 0.67% | -47.24% |
| 2018 | 1.27% | 139.62% |
| 2017 | 0.53% | -51.82% |
| 2016 | 1.10% | 92.98% |
| 2015 | 0.57% | -38.04% |
| 2014 | 0.92% | 12.20% |
| 2013 | 0.82% | -24.07% |
| 2012 | 1.08% | -68.79% |
| 2011 | 3.46% | 23.57% |
| 2010 | 2.80% | 83.01% |
| 2009 | 1.53% | -73.25% |
| 2008 | 5.72% | 40.89% |
| 2007 | 4.06% | -15.24% |
| 2006 | 4.79% | -55.40% |
| 2005 | 10.74% | 51.05% |
| 2004 | 7.11% | -15.76% |
| 2003 | 8.44% | -71.44% |
| 2002 | 29.55% | 34.50% |
| 2001 | 21.97% | 88.26% |
| 2000 | 11.67% | 0.00% |
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 1.57% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
